Envista Holdings Corporation
NVST
Positions held
Your positionsNVST isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Envista Holdings Corporation is well-positioned in the healthcare sector, focusing on innovative medical instruments and supplies, which are essential for the growing demand in dental and orthodontic markets.
- In Q2 2026, Envista reported a revenue increase of 4% compared to the previous quarter, reaching $730 million.
- The company's gross margin improved to 55.7% in Q2 2026, up from 55.3% in the prior quarter.
- Despite its potential, Envista faces challenges with a high trailing P/E ratio of 40.12, indicating that the stock may be overvalued compared to its earnings.
- In 2025, Envista reported a net income loss of $1118.6 million, highlighting significant financial struggles.
- The company's operating margin was only 8.67% in 2025, reflecting ongoing operational inefficiencies.
Fundamentals
| Market cap | $3.65B | Enterprise value | $4.11B | Trailing P/E | 39.17 | Forward P/E | 13.65 |
| PEG | — | Price / book | 1.19 | Beta | 0.89 | Dividend yield | 0.00% |
| Revenue growth | 7.1% | Earnings growth | 111.3% | Gross margin | 55.4% | Operating margin | 10.4% |
| Profit margin | 3.3% | ROE | 3.1% | ROA | 3.2% | Debt / equity | 0.52 |
| Current ratio | 2.43 | Free cash flow | $267.89M | Analyst recommendation | buy | Mean target | $29.69 |
| 52w high | $30.42 | 52w low | $18.77 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $731M | $706M | $751M | $670M | $682M | — |
| Op margin | 11.0% | 9.4% | 12.4% | 8.6% | 6.8% | — |
| Net income | $53.7M | $38.7M | $32.9M | -$30.3M | $26.4M | — |
| Gross margin | 55.7% | 55.3% | 54.7% | 55.3% | 54.2% | — |
| Gross profit | $407M | $390M | $411M | $370M | $370M | — |
| Operating income | $80.3M | $66.2M | $93.0M | $57.5M | $46.3M | — |
- Revenue +4% vs prior quarter ($730M vs $706M).
- Gross margin 55.7% (was 55.3% prior quarter).
- Operating margin expanded to 11%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.7B | $2.5B | $2.6B | $2.6B | — |
| Op margin | 8.7% | 5.5% | 12.3% | 13.4% | — |
| Net income | $47.0M | -$1.1B | -$100M | $243M | — |
| Gross margin | 54.7% | 54.7% | 56.1% | 57.4% | — |
| Gross profit | $1.5B | $1.4B | $1.4B | $1.5B | — |
| Operating income | $236M | $137M | $315M | $343M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · 3 Cash-Producing Stocks We Find Risky
2026-10-06 · Envista Schedules Third Quarter 2026 Earnings Call
2026-10-02 · 1 of Wall Street’s Favorite Stocks to Keep an Eye On and 2 We Ignore
2026-10-01 · Leaner Operations and Improving Dental Demand Position Envista Holdings Corp. (NVST) for Multi-Year Growth
2026-09-30 · Dental Equipment & Technology Stocks Q2 Earnings Review: Envista (NYSE:NVST) Shines
2026-09-28 · New Strong Buy Stocks for September 28th
2026-09-25 · NVST vs. ABT: Which Stock Is the Better Value Option?
2026-09-21 · Envista Holdings (NVST), Why Is Investor Attention Building Now?
2026-09-21 · Best Value Stocks to Buy for September 21st
2026-09-18 · Envista Stock Volatility Reflects Expectations, Not Negative News, UBS Says
2026-09-18 · Should Value Investors Buy Envista (NVST) Stock?
2026-09-18 · Down 12% in 4 Weeks, Here's Why You Should You Buy the Dip in Envista (NVST)
Price (daily)
Full chart · RSI · MACD · patterns